-
Uncategorized2 months agoA patent win for Pfizer and BridgeBio
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Several biotech leaders...
-
Uncategorized2 months ago
Chiesi signs $1.9B deal to acquire KalVista and its approved drug
Chiesi signs $1.9B deal to acquire KalVista and its approved drug
-
Uncategorized2 months ago
AstraZeneca bullish on $80B sales goal after beating expectations, Phase 3 data wins
After a quarter in which sales topped $15 billion and key readouts went AstraZeneca’s way, the company is increasingly confident that its 2030 revenue target is...
-
Uncategorized2 months ago
GSK’s Shingrix strategy shift drives sales beat even as vaccines slow
While sales for most of GSK’s shots slumped as vaccine skepticism continues to climb in the U.S., Shingrix jumped 20% to almost $1.4 billion in the...
-
Uncategorized2 months ago
Pfizer settles with generic drugmakers to protect blockbuster drug until 2031
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug that generated $3.8 billion in the...
-
Uncategorized2 months agoFood safety experts warn of USDA brain drain
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Morning. In the same way that Athena orchestrated...
-
Uncategorized2 months ago
AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions
AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions
-
Uncategorized2 months ago
Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’
Analysts will be watching as a generic version of semaglutide—marketed by Novo Nordisk as Wegovy for weight loss—launches in Canada as a test case for future...
-
Uncategorized2 months ago
GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readouts
GSK is expecting several key late-stage readouts this year and, if they do not succeed, the company could change its team structure, CEO Luke Miels said...
-
Uncategorized2 months ago
Q1 earnings take off, Lilly strikes many deals, Regeneron notches historic approval, FDA raises questions
Q1 earnings take off, Lilly strikes many deals, Regeneron notches historic approval, FDA raises questions
